HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Noriaki Tsubota Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Okada, M. Articles by Tsubota, N. Search for Related Content PubMed PubMed Citation Articles by Okada, M. Articles by Tsubota, N.

J Thorac Cardiovasc Surg 2000;119:814-819
© 2000 The American Association for Thoracic Surgery

GENERAL THORACIC SURGERY

SURVIVAL RELATED TO LYMPH NODE INVOLVEMENT IN LUNG CANCER AFTER SLEEVE LOBECTOMY COMPARED WITH PNEUMONECTOMY

From the Department of Thoracic Surgery, Hyogo Medical Center for Adults, Akashi City, Hyogo, and the Department of Thoracic Surgery, National Hyogo Central Hospital, Sanda City, Hyogo, Japan.

Address for reprints: Noriaki Tsubota, MD, Department of Thoracic Surgery, Hyogo Medical Center for Adults, Kitaohji-cho 13-70, Akashi City 673, Hyogo, Japan (E-mail: n-tsubo{at}sanynet.ne.jp ).

	Abstract

Top Abstract Introduction Patients and methods Results Discussion References

 
Objective: The purpose of this study was to compare the outcomes after sleeve lobectomy and pneumonectomy for patients with non–small cell lung cancer distributed according to their nodal involvement status.
Methods: Of 1172 patients in whom primary non–small cell lung carcinoma, including mediastinal lymph nodes, was completely excised, 151 patients underwent sleeve lobectomy and 60 underwent pneumonectomy. For bias reduction in comparison with a nonrandomized control group, we paired 60 patients undergoing sleeve lobectomy with 60 patients undergoing pneumonectomy by using the nearest available matching method.
Results: The 30-day postoperative mortality was 2% (1/60) in the pneumonectomy group and 0% in the sleeve lobectomy group. Postoperative complications occurred in 13% of patients in the sleeve lobectomy group and in 22% of those in the pneumonectomy group. Local recurrences occurred in 8% of patients in the sleeve lobectomy group and in 10% of those in the pneumonectomy group. The overall 5- and 10-year survivals for the sleeve lobectomy group were 48% and 36%, respectively, whereas those for the pneumonectomy group were 28% and 19%, respectively (P = .005). Multivariable analysis showed that the operative procedure, T factor, and N factor were significant independent prognostic factors and revealed that survival after sleeve lobectomy was significantly longer than that after pneumonectomy (P = .03).
Conclusions: These data suggest that sleeve lobectomy should be performed instead of pneumonectomy in patients with non–small cell lung cancer regardless of their nodal status whenever complete resection can be achieved because this is a lung-saving procedure with lower postoperative risks and is as curative as pneumonectomy.

	Introduction

Top Abstract Introduction Patients and methods Results Discussion References

 
Pneumonectomy, as compared with lobectomy, is associated with higher occurrence of postoperative complications, poor quality of life, and cardiopulmonary dysfunction. In addition, long-term complications (ie, the so-called postpneumonectomy syndrome presenting as late pulmonary hypertension or respiratory failure) are sometimes associated with pneumonectomy but seldom seen after lobectomy. Therefore pneumonectomy itself is thought to be a disease. Sleeve lobectomy, which allows preservation of functional lung parenchyma with the possible advantages of lower mortality and morbidity, is a valid alternative to pneumonectomy and is accepted as one of the standard treatments for lung cancer. ^1-3 We therefore have performed it frequently and actively in noncompromised patients or in patients with N2 disease. ^4,5 However, the long-term results after sleeve lobectomy remain controversial, especially in relation to nodal involvement. There have been only a few studies in which sleeve lobectomy and pneumonectomy have been compared with regard to survival according to nodal status, and the number of patients in the subgroup related to nodal status was small. ^3,6

We have reviewed our experience to compare sleeve lobectomy and pneumonectomy for non–small cell lung cancer in terms of survival and to determine significant factors related to survivals with special emphasis on nodal involvement.

	Patients and methods

Top Abstract Introduction Patients and methods Results Discussion References

 
Of 1370 patients who underwent operation for primary non–small cell lung cancer between June 1984 and December 1998, 1172 patients underwent curative surgery. Curative surgery was defined as complete removal of ipsilateral hilar and mediastinal lymph nodes together with the primary tumor. Sleeve lobectomy was done in 151 patients, standard (nonsleeve) lobectomy in 815, segmentectomy in 176, and pneumonectomy in 60. Sleeve lobectomy was usually done by choice in patients who would have been able to tolerate pneumonectomy but in whom the tumor could not have been removed by standard lobectomy and could be completely resected by a bronchoplastic procedure. Concomitant sleeve resection of the pulmonary artery (double sleeve resection) was required in 21 patients. Routine systematic dissection of all hilar and mediastinal nodes was performed in every case, even if the preoperative evaluation was N0 or N1. Every node dissected en bloc (not sampled) was examined by pathologists to be diagnosed as microscopically positive (cancerous) or negative (normal) during and after the operation. Patients who had evidence of residual tumor at the surgical margin, malignant effusion, or N3 disease verified by intraoperative findings or postoperative pathologic examination were considered to have undergone noncurative surgery ⁷ and were excluded from this study. Local recurrence was defined as any recurrence in the ipsilateral hemithorax. Operative mortality was defined as 30-day postoperative mortality plus intraoperative mortality. Resected specimens were examined histopathologically, and histologic typing was done according to the World Health Organization classification. ⁸ Surgical-pathologic staging was performed according to the New International Staging System for Lung Cancer. ⁹

To reduce the bias in the comparison of a nonrandomizcd control group, we paired the sleeve lobectomy group with the pneumonectomy group by using the nearest available matching method on the estimated propensity score. ¹⁰ Table I shows the characteristics of sleeve lobectomy and pneumonectomy groups. Categoric variables were analyzed by means of ² analysis and the unpaired t test. Survival was estimated by means of the Kaplan-Meier method, ¹¹ and differences in survival were determined by means of log-rank analysis. The results of the multivariable analysis of independent prognostic factors, which included sex, histologic type, T factor, N factor, and operative procedure, were assessed by using the Cox proportional hazards regression model. ¹² Zero time was the date of pulmonary resection, and the terminal event was death attributable to cancer, a cause other than cancer, or an unknown cause. Operative mortality was included.

	Results

Top Abstract Introduction Patients and methods Results Discussion References

As late complications after sleeve lobectomy, 2 (3%) patients had bronchial stricture, but they were both successfully treated with a bronchoscope and did not necessitate any operative repair, such as repeat sleeve resection or completion pneumonectomy. On the other hand, morbidity after pneumonectomy occurred in 22% (13/60) of the patients, consisting of pneumonia-atelectasis (n = 5), bronchopleural fistula (n = 4), cardiac herniation (n = 2), empyema (n = 1), and pulmonary infarction (n = 1).

Local recurrence developed in 5 (8%) patients after sleeve lobectomy and in 6 (10%) patients after pneumonectomy.

The 3-, 5-, and 10-year survivals were 61%, 48%, and 36% for patients subjected to sleeve lobectomy and 36%, 29%, and 19% for those subjected to pneumonectomy, respectively (Fig 1). Survival after sleeve lobectomy was significantly longer than that after pneumonectomy (P = .005). Among patients with N0 or N1 disease, the 3-, 5-, and 10-year survivals were 82%, 70%, and 55% for patients subjected to sleeve lobectomy and 50%, 42%, and 29% for patients who underwent pneumonectomy, respectively (Fig 2). A significant difference between the operative procedures was found among patients with N0 or N1 disease (P = .02). On the other hand, among patients with N2 disease, the 3- and 5-year survivals were 36% and 21% for patients who underwent sleeve lobectomy and 23% and 16% for those subjected to pneumonectomy, respectively (Fig 3). Among patients with N2 disease, there was a trend toward significance, although there was no significant difference (P = .09). Table II shows the results of the multivariable analysis of independent prognostic factors in patients with sleeve lobectomy or pneumonectomy, demonstrating that patients subjected to sleeve lobectomy had a significantly longer survival than those who underwent pneumonectomy (P = .03). In addition, T factor (P = .03) and N factor (P = .002) were shown to be significantly related to survival, and the latter factor affected survival most significantly.

View larger version (18K): [in this window] [in a new window]   Fig. 1. Cumulative survival curves of all patients who underwent complete resection for non–small cell lung cancer according to procedure. The survival of patients subjected to sleeve lobectomy was significantly longer than that of patients subjected to pneumonectomy (P = .005).

View larger version (16K): [in this window] [in a new window]   Fig. 2. Cumulative survival curves of patients with pN0 or pN1 disease who underwent complete resection for non–small cell lung cancer according to procedure. Patients in the sleeve lobectomy group survived significantly longer than those in the pneumonectomy group (P = .02).

View larger version (18K): [in this window] [in a new window]   Fig. 3. Cumulative survival curves of patients with pN2 disease who underwent complete resection for non–small cell lung cancer according to procedure. Patients in the sleeve lobectomy group tended to survive longer than those in the pneumonectomy group (P = .09).

	Discussion

Top Abstract Introduction Patients and methods Results Discussion References

In any case it is important to keep a macroscopically sufficient margin of safety and to obtain a rapid-frozen section intraoperatively. A major concern regarding bronchoplasty for malignancy might be the potentially increased incidence of local recurrence. The local recurrence after sleeve lobectomy was 13% in the review of Tedder and colleagues, ¹³ 23% in the series of Mehran and colleagues, ¹ and 20% in the report of Van Schil and colleagues. ² Local recurrence after sleeve lobectomy was found in 8% of our patients. Compared with pneumonectomy (10%), sleeve lobectomy was not associated with an increase in local recurrence.

The operative mortality for sleeve lobectomy in the review of Tedder and colleagues ¹³ was 6%, and it was 2% in the series of Mehran and colleagues. ¹ In our series no operative deaths occurred after sleeve lobectomy compared with 2% operative deaths after pneumonectomy. The rate of postoperative complications was lower after sleeve lobectomy (13%) than after pneumonectomy (22%). These data thus indicated the superiority of sleeve lobectomy over pneumonectomy. Pneumonectomy, which limits pulmonary reserve and results in an increased pulmonary artery pressure, leads to greater long-term cardiopulmonary disability and a worse quality of life than does lobectomy. ¹⁸ Also, pneumonectomy has been considered to be a predisposing, although not exclusively causative, factor for cardiopulmonary death. ¹⁹ We therefore consider that pneumonectomy is a disease in itself and should be avoided at all cost.

The relationship between survival after sleeve lobectomy and nodal involvement remains controversial. In our multivariable analysis, nodal status was the most significant factor related to survival, with N2 disease having a definitely negative effect compared with N0 or N1 disease. Mehran and colleagues ¹ demonstrated a significant difference in survival between N1 and N2 disease but not between N0 and N1 disease after sleeve resection and reported acceptable long-term prognosis in patients undergoing sleeve resection for lung cancer with N1 disease but not with N2 disease. Although the 5-year survival for patients with N2 disease after sleeve resection was shown to be 0% by Mehran and colleagues, ¹ it was 33% in the series of Naruke ²⁰ and 31% in the report of Van Schil and colleagues. ² The indication of sleeve lobectomy for patients with N2 disease (stage IIIA) is controversial and requires circumspection. We, however, do not think that pneumonectomy instead of sleeve lobectomy would have resulted in longer survival for patients with N2 disease because the cause of death in patients with N2 disease was mainly distant metastasis and not local recurrence.

Our multivariable analysis revealed that patients subjected to sleeve lobectomy could have a significantly better prognosis than those subjected to pneumonectomy regardless of sex, histologic type, pN factor, or pT factor. It was possible that patients who underwent pneumonectomy would have bigger more central tumors or more nodes involved, even if the stage was the same, which could affect the survival. In addition, the poor survival of patients with pneumonectomy might be due to functional or non–cancer-related reasons. This study demonstrated that sleeve lobectomy was a suitable surgical treatment for non–small cell lung cancer in terms of both operative risks and curability to say nothing of postoperative pulmonary function. We suggest that sleeve lobectomy should be performed for centrally located lung cancer whenever removal of the lesions is complete because this procedure accomplished a curability comparable with that of pneumonectomy, with the possible advantages of lower operative mortality and morbidity, equal if not better survival, and improved quality of life.

	References

Top Abstract Introduction Patients and methods Results Discussion References

 

1. Mehran RJ, Deslauriers J, Piraux M, Beaulieu M, Guimont C, Brisson J. Survival related to nodal status after sleeve resection for lung cancer. J Thorac Cardiovasc Surg 1994;107:576-83. [Abstract/Free Full Text]
   
2. Van Schil PE, Riviere AB, Knaepen PJ, Swieten HA, Reher SW, Goossens DJ, et al. Long-term survival after bronchial sleeve resection: univariate and multivariate analyses. Ann Thorac Surg 1996;61:1087-91. [Abstract/Free Full Text]
   
3. Gaissert HA, Mathisen DJ, Moncure AC, Hilgenberg AD, Grillo HC, Wain JC. Survival and function after sleeve lobectomy for lung cancer. J Thorac Cardiovasc Surg 1996;111:948-53. [Abstract/Free Full Text]
   
4. Okada M, Tsubota N, Yoshimura M, Miyamoto Y. Surgical approach for multiple primary lung carcinomas. J Thorac Cardiovasc Surg 1998;115:836-40. [Abstract/Free Full Text]
   
5. Okada M, Tsubota N, Yoshimura M, Miyamoto Y, Matsuoka H. Prognosis of completely resected pN2 non–small cell lung carcinomas. What is the significant node that affects survival? J Thorac Cardiovasc Surg 1999;118:270-5. [Abstract/Free Full Text]
   
6. Yoshino I, Yokoyama H, Yano T, Ueda T, Takai E, Mizutani K, et al. Comparison of the surgical results of lobectomy with bronchoplasty and pneumonectomy for lung cancer. J Surg Oncol 1997;64:32-5. [Medline]
   
7. Okada M, Tsubota N, Yoshimura M, Miyamoto Y, Maniwa Y. Role of pleural lavage cytology before resection for primary lung carcinomas. Ann Surg 1999;229:579-84. [Medline]
   
8. World Health Organization histologic typing of lung turnouts. 2nd ed. Am J Clin Pathol 1982;77:123-36. [Medline]
   
9. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997;111:1710-7. [Abstract/Free Full Text]
   
10. D’Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a non-randomized control group. Stat Med 1998;17:2265-81. [Medline]
    
11. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
    
12. Cox DW. Regression models and life tables. J R Stat Soc 1972;34:187-220.
    
13. Tedder M, Anstadt M, Tedder S, Lowe JM. Current morbidity, mortality, and survival after bronchoplastic procedures for malignancy. Ann Thorac Surg 1992;54:387-91. [Abstract]
    
14. Lowe JE, Sabiston DC Jr. Bronchoplastic techniques in the surgical management of benign and malignant pulmonary lesions. In: Sabiston DC Jr, Spencer FC, editors. Surgery of the chest. Philadelphia: WB Saunders; 1990. p. 577.
    
15. Tsubota N, Yoshimura M, Murotani A, Miyamoto Y, Matoba Y. One hundred and one cases of bronchoplasty for primary lung cancer. Surg Today 1994;24:978-81. [Medline]
    
16. Okada M, Tsubota N, Yoshimura M, Miyamoto Y. Proposal for reasonable mediastinal lymphadenectomy in bronchogenic carcinomas: role of subcarinal node in selective dissection. J Thorac Cardiovasc Surg 1998;116:949-53. [Abstract/Free Full Text]
    
17. Okada M, Tsubota N, Yoshimura M, Miyamoto Y, Matsuoka H, Satake S, et al. Extended sleeve lobectomy for lung cancer to avoid pneumonectomy. J Thorac Cardiovasc Surg 1999;118:710-4. [Abstract/Free Full Text]
    
18. Rocco PM, Antkowiak JG, Takita H, Urschel JD. Long-term outcome after pneumonectomy for nonsmall cell lung cancer. J Surg Oncology 1996;61:278-80. [Medline]
    
19. Shields TW, Humphrey EW, Higgins GA, Keehn RJ. Long-term survivors after resection of lung carcinoma. J Thorac Cardiovasc Surg 1978;76:439-45. [Medline]
    
20. Naruke T. Bronchoplastic and bronchovascular procedures of the tracheobronchial tree in the management of primary lung cancer. Chest 1989;96(Suppl):53S-6S. [Free Full Text]
    

This article has been cited by other articles:

				M. Konstantinou, K. Potaris, T. Sakellaridis, and G. Chamalakis Sleeve lobectomy for patients with non-small-cell lung cancer: a simplified approach Eur. J. Cardiothorac. Surg., December 1, 2009; 36(6): 1045 - 1049. [Abstract] [Full Text] [PDF]

				R. E. Merritt, D. J. Mathisen, J. C. Wain, H. A. Gaissert, D. Donahue, M. Lanuti, J. S. Allan, C. R. Morse, and C. D. Wright Long-term results of sleeve lobectomy in the management of non-small cell lung carcinoma and low-grade neoplasms. Ann. Thorac. Surg., November 1, 2009; 88(5): 1574 - 1582. [Abstract] [Full Text] [PDF]

				F. Venuta, A. M. Ciccone, M. Anile, M. Ibrahim, T. De Giacomo, G. F. Coloni, and E. A. Rendina Reconstruction of the pulmonary artery for lung cancer: Long-term results J. Thorac. Cardiovasc. Surg., November 1, 2009; 138(5): 1185 - 1191. [Abstract] [Full Text] [PDF]

				A. Demir, A. Turna, C. Kocaturk, M. Z. Gunluoglu, U. Aydogmus, N. Urer, M. A. Bedirhan, A. Gurses, and S. I. Dincer Prognostic Significance of Surgical-Pathologic N1 Lymph Node Involvement in Non-Small Cell Lung Cancer Ann. Thorac. Surg., April 1, 2009; 87(4): 1014 - 1022. [Abstract] [Full Text] [PDF]

				H. Parissis, M. Leotsinidis, A. Hughes, E. McGovern, D. Luke, and V. Young Comparative Analysis and Outcomes of Sleeve Resection Versus Pneumonectomy Asian Cardiovasc Thorac Ann, April 1, 2009; 17(2): 175 - 182. [Abstract] [Full Text] [PDF]

				M. Chida, M. Minowa, S. Miyoshi, and T. Kondo Extended sleeve lobectomy for locally advanced lung cancer. Ann. Thorac. Surg., March 1, 2009; 87(3): 900 - 905. [Abstract] [Full Text] [PDF]

				K. Yamamoto, Y. Miyamoto, A. Ohsumi, F. Kojima, N. Imanishi, K. Matsuoka, M. Ueda, and C. Hamada Sleeve lung resection for lung cancer: Analysis according to the type of procedure. J. Thorac. Cardiovasc. Surg., November 1, 2008; 136(5): 1349 - 1356. [Abstract] [Full Text] [PDF]

				Z. Ma, A. Dong, J. Fan, and H. Cheng Does sleeve lobectomy concomitant with or without pulmonary artery reconstruction (double sleeve) have favorable results for non-small cell lung cancer compared with pneumonectomy? A meta-analysis Eur. J. Cardiothorac. Surg., July 1, 2007; 32(1): 20 - 28. [Abstract] [Full Text] [PDF]

				B. Yildizeli, E. Fadel, S. Mussot, D. Fabre, O. Chataigner, and P. G. Dartevelle Morbidity, mortality, and long-term survival after sleeve lobectomy for non-small cell lung cancer Eur. J. Cardiothorac. Surg., January 1, 2007; 31(1): 95 - 102. [Abstract] [Full Text] [PDF]

				T. Nagayasu, K. Matsumoto, T. Tagawa, A. Nakamura, N. Yamasaki, and A. Nanashima Factors affecting survival after bronchoplasty and broncho-angioplasty for lung cancer: single institutional review of 147 patients. Eur. J. Cardiothorac. Surg., April 1, 2006; 29(4): 585 - 590. [Abstract] [Full Text] [PDF]

				S.-i. Takeda, H. Maeda, M. Koma, Y. Matsubara, N. Sawabata, M. Inoue, T. Tokunaga, and M. Ohta Comparison of surgical results after pneumonectomy and sleeve lobectomy for non-small cell lung cancer.: Trends over time and 20-year institutional experience Eur. J. Cardiothorac. Surg., March 1, 2006; 29(3): 276 - 280. [Abstract] [Full Text] [PDF]

				P. Bagan, P. Berna, J. C. Das Neves Pereira, F. Le Pimpec Barthes, C. Foucault, A. Dujon, and M. Riquet Sleeve Lobectomy Versus Pneumonectomy: Tumor Characteristics and Comparative Analysis of Feasibility and Results Ann. Thorac. Surg., December 1, 2005; 80(6): 2046 - 2050. [Abstract] [Full Text] [PDF]

				M. Okada, T. Sakamoto, T. Yuki, T. Mimura, K. Miyoshi, and N. Tsubota Hybrid Surgical Approach of Video-Assisted Minithoracotomy for Lung Cancer: Significance of Direct Visualization on Quality of Surgery Chest, October 1, 2005; 128(4): 2696 - 2701. [Abstract] [Full Text] [PDF]

				C. A. DiPerna and D. E. Wood Surgical Management of T3 and T4 Lung Cancer Clin. Cancer Res., July 1, 2005; 11(13): 5038s - 5044s. [Abstract] [Full Text] [PDF]

				M. Ibrahim, F. Venuta, and E. A. Rendina Bronchial and pulmonary arterial sleeve resection MMCTS, April 25, 2005; 2005(0425): 67. [Abstract] [Full Text] [PDF]

				Y. T. Kim, C. H. Kang, S. W. Sung, and J. H. Kim Local Control of Disease Related to Lymph Node Involvement in Non-Small Cell Lung Cancer After Sleeve Lobectomy Compared With Pneumonectomy Ann. Thorac. Surg., April 1, 2005; 79(4): 1153 - 1161. [Abstract] [Full Text] [PDF]

				C. Ludwig, E. Stoelben, M. Olschewski, and J. Hasse Comparison of Morbidity, 30-Day Mortality, and Long-Term Survival After Pneumonectomy and Sleeve Lobectomy For Non-Small Cell Lung Carcinoma Ann. Thorac. Surg., March 1, 2005; 79(3): 968 - 973. [Abstract] [Full Text] [PDF]

				M. Okada, W. Nishio, T. Sakamoto, K. Uchino, T. Yuki, A. Nakagawa, and N. Tsubota Sleeve segmentectomy for non-small cell lung carcinoma J. Thorac. Cardiovasc. Surg., September 1, 2004; 128(3): 420 - 424. [Abstract] [Full Text] [PDF]

				J. Deslauriers, J. Gregoire, L. F. Jacques, M. Piraux, L. Guojin, and Y. Lacasse Sleeve lobectomy versus pneumonectomy for lung cancer: a comparative analysis of survival and sites or recurrences Ann. Thorac. Surg., April 1, 2004; 77(4): 1152 - 1156. [Abstract] [Full Text] [PDF]

				M. K. Ferguson and A. G. Lehman Sleeve lobectomy or pneumonectomy: optimal management strategy using decision analysis techniques Ann. Thorac. Surg., December 1, 2003; 76(6): 1782 - 1788. [Abstract] [Full Text] [PDF]

				M. Okada, W. Nishio, T. Sakamoto, H. Harada, K. Uchino, and N. Tsubota Long-term survival and prognostic factors of five-year survivors with complete resection of non-small cell lung carcinoma J. Thorac. Cardiovasc. Surg., August 1, 2003; 126(2): 558 - 562. [Abstract] [Full Text] [PDF]

				W. J. Scott, J. Howington, and B. Movsas Treatment of Stage II Non-small Cell Lung Cancer Chest, January 1, 2003; 123 (2009): 188S - 201S. [Abstract] [Full Text] [PDF]

				E. Fadel, B. Yildizeli, A. R. Chapelier, I. Dicenta, S. Mussot, and P. G. Dartevelle Sleeve lobectomy for bronchogenic cancers: factors affecting survival Ann. Thorac. Surg., September 1, 2002; 74(3): 851 - 859. [Abstract] [Full Text] [PDF]

				M. Okada, K. Yoshikawa, T. Hatta, and N. Tsubota Is segmentectomy with lymph node assessment an alternative to lobectomy for non-small cell lung cancer of 2 cm or smaller? Ann. Thorac. Surg., March 1, 2001; 71(3): 956 - 960. [Abstract] [Full Text] [PDF]

				P. E. Van Schil Sleeve lobectomy and lymph node involvement J. Thorac. Cardiovasc. Surg., February 1, 2001; 121(2): 399 - 399. [Full Text] [PDF]

				N. Tsubota Reply J. Thorac. Cardiovasc. Surg., February 1, 2001; 121(2): 399 - 340. [Full Text] [PDF]

				M. Okada, N. Tsubota, M. Yoshimura, Y. Miyamoto, and H. Matsuoka Induction Therapy for Non-small Cell Lung Cancer With Involved Mediastinal Nodes in Multiple Stations Chest, July 1, 2000; 118(1): 123 - 128. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Noriaki Tsubota Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Okada, M. Articles by Tsubota, N. Search for Related Content PubMed PubMed Citation Articles by Okada, M. Articles by Tsubota, N.